UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in CVS Health Corporation $CVS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 7.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,684,996 shares of the pharmacy operator's stock after selling 613,102 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.60% of CVS Health worth $795,013,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in CVS Health in the second quarter worth about $12,747,462,000. State Street Corp boosted its holdings in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock valued at $4,776,182,000 after acquiring an additional 1,245,457 shares during the period. Wellington Management Group LLP increased its stake in CVS Health by 49.8% in the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after purchasing an additional 11,233,381 shares during the period. Capital International Investors boosted its stake in shares of CVS Health by 3.4% during the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator's stock valued at $2,189,793,000 after purchasing an additional 900,153 shares during the period. Finally, Bank of America Corp DE increased its stake in CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after buying an additional 13,836,701 shares during the period. Institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 0.2%

CVS Health stock opened at $93.15 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market cap of $119.14 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 0.91 and a beta of 0.61. The stock has a 50-day moving average of $101.42 and a two-hundred day moving average of $89.46. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. During the same period last year, the business earned $1.81 EPS. CVS Health's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's dividend payout ratio is currently 70.37%.

Wall Street Analysts Forecast Growth

Several research firms have commented on CVS. Wall Street Zen upgraded CVS Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Weiss Ratings raised shares of CVS Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 5th. Mizuho upped their target price on CVS Health from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Monday, June 8th. Cantor Fitzgerald increased their target price on CVS Health from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $107.17.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS' Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source